Cargando…

Identification of CD318 (CDCP1) as novel prognostic marker in AML

Genetic and morphological markers are well-established prognostic factors in acute myeloid leukemia (AML). However, further reliable markers are urgently needed to improve risk stratification in AML. CD318 (CDCP1) is a transmembrane protein which in solid tumors promotes formation of metastasis and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heitmann, Jonas S., Hagelstein, Ilona, Hinterleitner, Clemens, Roerden, Malte, Jung, Gundram, Salih, Helmut R., Märklin, Melanie, Kauer, Joseph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060168/ https://www.ncbi.nlm.nih.gov/pubmed/31965270 http://dx.doi.org/10.1007/s00277-020-03907-9

Ejemplares similares

CD105 (Endoglin) as negative prognostic factor in AML
por: Kauer, Joseph, et al.
Publicado: (2019)

Identification of CD105 (endoglin) as novel risk marker in CLL
por: Greiner, Sarah M., et al.
Publicado: (2022)

DNAM-1/CD226 is functionally expressed on acute myeloid leukemia (AML) cells and is associated with favorable prognosis
por: Chashchina, Anna, et al.
Publicado: (2021)

Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas
por: Hagelstein, Ilona, et al.
Publicado: (2021)

BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro
por: Kauer, Joseph, et al.
Publicado: (2022)

B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma
por: Hagelstein, Ilona, et al.
Publicado: (2022)

CD18 Antibody Application Blocks Unwanted Off-Target T Cell Activation Caused by Bispecific Antibodies
por: Kauer, Joseph, et al.
Publicado: (2021)

Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies
por: Lutz, Martina Svenja, et al.
Publicado: (2022)

Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
por: Märklin, Melanie, et al.
Publicado: (2019)

Expression of the Immune Checkpoint Modulator OX40 in Acute Lymphoblastic Leukemia Is Associated with BCR-ABL Positivity()
por: Rothfelder, Kathrin, et al.
Publicado: (2018)

A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL
por: Mehta, Naveen K, et al.
Publicado: (2022)

Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia
por: Marconato, Maddalena, et al.
Publicado: (2022)

Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies
por: Kauer, Joseph, et al.
Publicado: (2020)

HLA Evolutionary Divergence as a Prognostic Marker for AML Patients Undergoing Allogeneic Stem Cell Transplantation
por: Roerden, Malte, et al.
Publicado: (2020)

An Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity against B Cell Acute Lymphoblastic Leukemia
por: Riegg, Fabian, et al.
Publicado: (2021)

Immunoprofiling of 4-1BB Expression Predicts Outcome in Chronic Lymphocytic Leukemia (CLL)
por: Kaban, Kübra, et al.
Publicado: (2021)

Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma
por: Heitmann, Jonas S, et al.
Publicado: (2020)

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
por: Heitmann, Jonas S., et al.
Publicado: (2023)

IgG-Based Bispecific Anti-CD95 Antibodies for the Treatment of B Cell-Derived Malignancies and Autoimmune Diseases
por: Hörner, Sebastian, et al.
Publicado: (2022)

An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer
por: Zekri, Latifa, et al.
Publicado: (2020)

Targeting NKG2DL with Bispecific NKG2D–CD16 and NKG2D–CD3 Fusion Proteins on Triple–Negative Breast Cancer
por: Kaidun, Polina, et al.
Publicado: (2023)

Therapeutic Silencing of BCL-2 Using NK Cell-Derived Exosomes as a Novel Therapeutic Approach in Breast Cancer
por: Kaban, Kübra, et al.
Publicado: (2021)

Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives
por: Heitmann, Jonas S., et al.
Publicado: (2021)

T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals
por: Bilich, Tatjana, et al.
Publicado: (2021)

Genetic Loss of LCK Kinase Leads to Acceleration of Chronic Lymphocytic Leukemia
por: Märklin, Melanie, et al.
Publicado: (2020)

IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer
por: Lutz, Martina S., et al.
Publicado: (2023)

Regulation of Platelet-Derived ADAM17: A Biomarker Approach for Breast Cancer?
por: Zhou, Yanjun, et al.
Publicado: (2021)

Platelet-Expressed TNFRSF13B (TACI) Predicts Breast Cancer Progression
por: Hinterleitner, Clemens, et al.
Publicado: (2021)

Platelet-expressed immune checkpoint regulator GITRL in breast cancer
por: Zhou, Yanjun, et al.
Publicado: (2021)

CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers
por: Turdo, Federica, et al.
Publicado: (2016)

Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody
por: Schmied, Bastian J., et al.
Publicado: (2019)

Receptor Activator of NF-κB (RANK) Confers Resistance to Chemotherapy in AML and Associates with Dismal Disease Course
por: Clar, Kim L., et al.
Publicado: (2021)

CDCP1 Identifies a CD146 Negative Subset of Marrow Fibroblasts Involved with Cytokine Production
por: Iwata, Mineo, et al.
Publicado: (2014)

The challenges of translation
por: Salih, Helmut R, et al.
Publicado: (2019)

Health Tract No. 318: Recognition Hereafter
Publicado: (1868)

Dysregulated expression of cell surface glycoprotein CDCP1 in prostate cancer
por: Yang, Lifang, et al.
Publicado: (2015)

Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer
por: Harrington, Brittney S., et al.
Publicado: (2020)

Draft Genome Sequence of Lactobacillus paraplantarum OSY-TC318, a Producer of the Novel Lantibiotic Paraplantaracin TC318
por: Hussein, Walaa E., et al.
Publicado: (2019)

Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia
por: Nelde, Annika, et al.
Publicado: (2021)

Inhibition of NK Reactivity Against Solid Tumors by Platelet-Derived RANKL
por: Clar, Kim L., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0raca5le1tdaeqjaaguar4r07c